Smaller than expected sales decline in Novo Nordisk's biopharma division
According to estimates compiled by Novo Nordisk, analysts had expected total sales of biopharmaceutical products for rare diseases of DKK 4404 million.
by marketwire
Novo Nordisk’s sales of rare disease drugs shrank less than expected to DKK 4571m (USD 663m) in the fourth quarter last year from DKK 4853m in the same period last year, according to the pharmaceutical group’s annual report published on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
